Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BIO 11006

Next Previous
Drug Profile

BIO 11006

Alternative Names: BIO-11006; BIO-11006 Inhalation Solution

Latest Information Update: 29 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator North Carolina State University
  • Developer BioMarck Pharmaceuticals
  • Class Antineoplastics; Expectorants; Immunotherapies; Peptides
  • Mechanism of Action Myristoylated alanine rich C kinase substrate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adult respiratory distress syndrome; Chronic obstructive pulmonary disease; Ewing's sarcoma; Osteosarcoma
  • No development reported Lung cancer; Neuroblastoma; Non-small cell lung cancer; Rhabdomyosarcoma

Most Recent Events

  • 29 Nov 2022 Phase-II development is ongoing in Osteosarcoma and Ewing's Sarcoma (In adults, In children, Metastatic disease) in USA (Inhalation) (NCT04183062)
  • 29 Nov 2022 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease) in India (Inhalation) (NCT03472053)
  • 14 May 2021 Interim adverse events data from a phase IIa trial in Adult respiratory distress syndrome presented at the 117th International Conference of the American Thoracic Society (ATS-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top